0001485003-23-000111.txt : 20230306
0001485003-23-000111.hdr.sgml : 20230306
20230306204640
ACCESSION NUMBER: 0001485003-23-000111
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230302
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sullivan Mark
CENTRAL INDEX KEY: 0001331843
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36296
FILM NUMBER: 23710783
MAIL ADDRESS:
STREET 1: 1000 BISHOPS GATE BOULEVARD
STREET 2: SUITE 300
CITY: MOUNT LAUREL
STATE: NJ
ZIP: 08054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sesen Bio, Inc.
CENTRAL INDEX KEY: 0001485003
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262025616
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-444-8550
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc.
DATE OF NAME CHANGE: 20100223
4
1
wf-form4_167815358414793.xml
FORM 4
X0306
4
2023-03-02
0
0001485003
Sesen Bio, Inc.
SESN
0001331843
Sullivan Mark
C/O SESEN BIO, INC.
245 FIRST STREET, SUITE 1800
CAMBRIDGE
MA
02142
0
1
0
0
General Counsel & Secretary
Common Stock
2023-03-02
4
S
0
100978
0.587
D
198716
D
Common Stock
2023-03-02
4
M
0
185000
0.587
A
383716
D
Common Stock
2023-03-02
4
S
0
73361
0.587
D
310355
D
Common Stock
2023-03-02
4
M
0
113175
0.587
A
423530
D
Common Stock
2023-03-02
4
S
0
44879
0.587
D
378651
D
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above.
Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 21, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
/s/ Mark R. Sullivan
2023-03-06